1. Home
  2. BMEZ vs ESPR Comparison

BMEZ vs ESPR Comparison

Compare BMEZ & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock Health Sciences Term Trust of Beneficial Interest

BMEZ

BlackRock Health Sciences Term Trust of Beneficial Interest

HOLD

Current Price

$14.59

Market Cap

871.9M

Sector

Finance

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$2.11

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMEZ
ESPR
Founded
N/A
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
871.9M
731.9M
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
BMEZ
ESPR
Price
$14.59
$2.11
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.60
AVG Volume (30 Days)
230.2K
6.3M
Earning Date
01-01-0001
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.71
EPS
N/A
N/A
Revenue
N/A
$403,135,000.00
Revenue This Year
N/A
$1.53
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.31
52 Week Low
$13.40
$0.73
52 Week High
$15.80
$4.18

Technical Indicators

Market Signals
Indicator
BMEZ
ESPR
Relative Strength Index (RSI) 54.43 33.85
Support Level $13.78 $1.02
Resistance Level $14.61 $2.99
Average True Range (ATR) 0.23 0.19
MACD 0.08 -0.03
Stochastic Oscillator 71.43 6.37

Price Performance

Historical Comparison
BMEZ
ESPR

About BMEZ BlackRock Health Sciences Term Trust of Beneficial Interest

BlackRock Health Sciences Term Trust is a closed-end fund focused on the healthcare and health sciences sector. Its investment objectives are to provide total return and income through long-term capital appreciation.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: